PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY

Not Applicable

Completed

• Conditions: Respiratory Depression
• Interventions: Device: Capnostream Monitor

• Registration Number: NCT02811302
• Lead Sponsor: Medtronic - MITG

Brief Summary

PRODIGY is a prospective, multi-center, post-market, international cohort study. The primary objective of this study is to derive a score to identify subjects at risk to have respiratory depression (RD) episodes in patients undergoing opioid therapy in the hospital ward and monitored by capnography. The score will be derived by using subjects within the derivation cohort and internally validated using subjects within the validation cohort.

The primary endpoint used to derive the score will be the occurrence of RD episodes derived by Capnostream 20p device memory data combined with clinical data and validated by an independent Clinical Endpoint Committee (CEC) during the study course.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-06-21
• Study First Submitted QC: 2016-06-21
• Study First Posted: 2016-06-23
• Study Start: 2017-04-07
• Primary Completion: 2018-05-07
• Study Completion: 2018-05-07
• Status Verified: 2019-04
• Results First Submitted: 2019-04-25
• Results First Submitted QC: 2019-05-17
• Last Update Submitted: 2019-05-17
• Results First Posted: 2019-06-12
• Last Update Posted: 2019-06-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1495

Inclusion Criteria

1. Patients receiving parenteral opioid therapy (for post-surgical or non-surgical) pain on the hospital ward.
2. Adult age (≥18 year old in US and Europe; ≥20 years old in Japan; ≥21 years old in Singapore).
3. Patient is able and willing to give informed consent.

Exclusion Criteria

1. Expected length of stay ≤ 24 hours.
2. Patient is receiving intrathecal opioids.
3. Post-surgical patients with American Society of Anesthesiologists physical status (ASA PS) V or higher.
4. Patients with the status of Do Not Resuscitate (DNR), hospice, or receiving end of life therapy.
5. Ventilated or intubated patients.
6. Patient is unwilling or unable to comply fully with study procedures (including non-toleration of the capnography cannula) due to any disease condition which can raise doubt about compliance and influencing the study outcome.
7. Patient is a member of a vulnerable population, including legal incapacity or evidence that a subject cannot understand the purpose and risks of the study, regardless of authorized representative support.
8. Patient is participating in another potentially confounding drug or device clinical study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients monitored by capnography	Capnostream Monitor	Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.

Primary Outcome Measures

Name	Time	Method
Determine Number of Subjects With RD While on Opioid Therapy	48 hours	Continuous respiratory monitoring using a Capnostream monitor will be included for collecting data for end tidal carbon dioxide (etCO2) and Oxygen saturation (SpO2). Positive RD determination was provided by an independent Clinical Event Committee, by assessing the following parameters: * etCO2 ≤ 15 or ≥ 60 mmHg for ≥ 3 minutes, or; * RR ≤ 5 breaths for ≥ 3 minutes, or; * SpO2 ≤ 85% for ≥ 3 minutes, or; * Apnea episode lasting \> 30 seconds, or; * Any respiratory Opioid-Related Adverse Event (rORADE).
To Derive and Validate a Risk Assessment Tool to Identify Subjects at Risk of Having RD While Undergoing Opioid Therapy on the Hospital Ward	48 hours	A risk assessment tool will be derived and validated using the incidence of RD episodes captured by continuous capnography and pulse oximetry measurements recorded on the Capnostream device memory data in conjunction with the clinical data as reported by the investigator.

Trial Locations

Locations (16)

University of Colorado Hospital; 🇺🇸 Aurora, Colorado, United States

Maastricht UMC+; 🇳🇱 Maastricht, Limburg, Netherlands

National University Hospital; 🇸🇬 Singapore, Singapore

Emory University Hospital; 🇺🇸 Atlanta, Georgia, United States

Beaumont Hospital - Royal Oak; 🇺🇸 Royal Oak, Michigan, United States

MetroHealth Medical Center; 🇺🇸 Cleveland, Ohio, United States

Brigham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States

The Ohio State University Wexner Medical Center; 🇺🇸 Columbus, Ohio, United States

Buffalo General Medical Center; 🇺🇸 Buffalo, New York, United States

Providence Regional Medical Center Everett; 🇺🇸 Everett, Washington, United States

Hospital Foch; 🇫🇷 Suresnes, France

The Jikei University School of Medicine Hospital; 🇯🇵 Tokyo, Japan

University Hospital Bonn; 🇩🇪 Bonn, Germany

Okayama University Hospital; 🇯🇵 Okayama, Japan

Hospital Clínico Universitario de Valencia; 🇪🇸 Valencia, Spain

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States